Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Wrigley

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Healthcare division has signed a $25 mil. agreement to acquire complete assets of Gum Tech's gum business, firm announces March 15. Under the deal, Wrigley will obtain rights to Gum Tech's manufacturing facility and plant as well as existing manufacturing contracts. Gum Tech will retain its interest in Gel Tech and its joint venture with Swedish Match. Wrigley said the acquisition will enable its new healthcare division to more quickly and cost effectively develop innovative products than it would have by building its own facility. Wrigley Healthcare began shipping Surpass antacid chewing gum, its first OTC product, Feb. 19 (1"The Tan Sheet" Feb. 19, p. 8)

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

See All
UsernamePublicRestriction

Register

PS092324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By